← Back to Clinical Trials
Recruiting NCT06266455

NCT06266455 Individualized Nutrition to Optimize Preterm Infant Growth and Neurodevelopment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06266455
Status Recruiting
Phase —
Sponsor Children's National Research Institute
Condition Very Preterm Maturity of Infant
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2024-02-08
Primary Completion 2034-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 4 Weeks
Study Type INTERVENTIONAL
Interventions
Standardized FortificationAdjustable FortificationAdjustable Fortification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2024-02-08 with a primary completion date of 2034-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Human milk has several well-established benefits but does not adequately meet the increased nutritional demands of the growing preterm infant, necessitating additional nutrient supplementation in a process known as fortification. In U.S. neonatal intensive care units (NICUs), human milk is primarily supplemented using standardized fortification, in which a multicomponent fortifier is added to human milk to achieve assumed nutrient content based on standard milk reference values. However, this method does not account for the significant variability in human milk composition or in preterm infant metabolism, and up to half of all very premature infants experience poor growth and malnutrition using current nutritional practices. Poor postnatal growth has adverse implications for the developing preterm brain and long-term neurodevelopment. Recent advances allow for individualized methods of human milk fortification, including adjustable and targeted fortification. Adjustable fortification uses laboratory markers of protein metabolism (BUN level) to estimate an infant's protein requirements. In targeted fortification, a milk sample is analyzed to determine its specific macronutrient and energy content, with additional macronutrient supplementation provided as needed to achieve goal values. Emerging data suggest that both methods are safe and effective for improving growth, however information on their comparable efficacy and neurodevelopmental implications are lacking, particularly using advanced quantitative brain MRI (qMRI) techniques. Through this prospective, randomized-controlled trial, the investigators will compare the impact of individualized human milk fortification on somatic growth and neurodevelopment in preterm infants. Infants will be randomized to receive one of three nutritional interventions: standardized (control group), adjustable, or targeted human milk fortification. Infants will undergo their assigned nutritional intervention until term-equivalent age or discharge home, whichever is achieved first. Brain qMRI will be performed at term-corrected age, and neurodevelopmental follow-up will be performed through 5 years of age.

Eligibility Criteria

Inclusion Criteria: * Birth gestational age (GA) of ≤32 weeks * Postnatal age ≤4 weeks at time of enrollment * Maternal plan to provide human milk to infant, and consent to providing donor human milk if insufficient maternal milk supply * Maternal age \> 18 years old Exclusion Criteria: * Formula feeding prior to 36 weeks PMA or discharge home (whichever achieved first), either secondary to parental preference or medical necessity * Dysmorphic features or congenital anomalies suggestive of a genetic syndrome, metabolic disorder, chromosomal abnormality, or congenital infection * Dysgenetic or major destructive brain lesions detected by head ultrasound before enrollment

Contact & Investigator

Central Contact

Catherine Limperopoulos, Ph.D.

✉ CLimpero@childrensnational.org

📞 202-476-5293

Frequently Asked Questions

Who can join the NCT06266455 clinical trial?

This trial is open to participants of all sexes, up to 4 Weeks, studying Very Preterm Maturity of Infant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06266455 currently recruiting?

Yes, NCT06266455 is actively recruiting participants. Contact the research team at CLimpero@childrensnational.org for enrollment information.

Where is the NCT06266455 trial being conducted?

This trial is being conducted at Washington D.C., United States.

Who is sponsoring the NCT06266455 clinical trial?

NCT06266455 is sponsored by Children's National Research Institute. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology